To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
NCT07730619 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 140
Last updated 2026-07-28
Summary
In recent years, an increasing number of patients who have experienced poor efficacy or adverse drug reactions using traditional treatment regimens have received biologic therapy and achieved satisfactory treatment results. However, we also found that some patients have poor reactions to biological agents. Biological agents are often the final treatment choice for most patients, and patients often have high expectations for this treatment plan. Therefore, exploring the factors that affect the efficacy of biological agents and effective follow-up treatment plans when there is poor response to biological agents is of great significance for the treatment of psoriasis patients.
The main research objective of this project is to observe and record the clinical characteristics and efficacy of plaque psoriasis patients treated with biological agents in the real world. 2. Explore the influencing factors of recurrence in plaque psoriasis patients receiving biological therapy in the real world, in order to increase awareness and awareness of this phenomenon, and provide guidance for preventing recurrence after biological therapy. 3. Record the follow-up treatment plans or response measures for recurrent patients, and compare the efficacy of different treatment plans.
This study is a case-control study that recruited patients with plaque psoriasis who have received biological therapy for more than half a year. A questionnaire survey was conducted to understand their general information, disease-related clinical data, and laboratory examination data. Univariate analysis was used to compare all variables between groups, and logistic regression analysis was performed on variables with statistical differences. Corresponding ROC curves were then drawn. Perform a separate analysis of the Adalimumab group according to the above steps. In addition, descriptive analysis was conducted on the characteristics that may be related to the disease in the recurrence group, and the efficacy of different treatment plans after recurrence was compared.
Conditions
- Plaque Psoriasis
- Biologic Agents
- Relapse
- Influence Factors
Interventions
- DIAGNOSTIC_TEST
-
Diagnosis and Physical Examination of Psoriasis
This study divided patients with plaque psoriasis treated with biological agents into a recurrent group and a non recurrent group based on whether they recurred or not
Sponsors & Collaborators
-
First Affiliated Hospital Xi'an Jiaotong University
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2026-12-01
- Completion
- 2026-12-30
Countries
- China
Study Locations
More Related Trials
-
Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity
NCT02602925 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis
NCT01504113 ·Status: UNKNOWN
-
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
NCT01871402 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02223039 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
NCT03236870 ·Status: COMPLETED
-
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial(REACT)
NCT05863273 ·Status: COMPLETED
-
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT07251998 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
NCT01988103 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
NCT02144857 ·Status: UNKNOWN ·Phase: PHASE4
-
Regulation of Inflammatory Genes in Psoriasis
NCT03125655 ·Status: RECRUITING
-
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
NCT04612699 ·Status: COMPLETED ·Phase: PHASE2
-
Apremilast in Palmo-Plantar Psoriasis
NCT02400749 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
NCT03020199 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00794807 ·Status: COMPLETED ·Phase: PHASE4
-
Sulodexide in Controlling the Recurrence of Psoriasis
NCT06982196 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis
NCT01177800 ·Status: COMPLETED ·Phase: PHASE3
-
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
NCT05503875 ·Status: RECRUITING ·Phase: NA
-
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
NCT05547490 ·Status: COMPLETED
-
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
NCT05120297 ·Status: COMPLETED ·Phase: PHASE3
-
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
NCT05655299 ·Status: TERMINATED ·Phase: PHASE2
-
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
NCT05111210 ·Status: RECRUITING
-
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
NCT02330380 ·Status: COMPLETED
-
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
NCT05223868 ·Status: COMPLETED ·Phase: PHASE2
-
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
NCT05725057 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06167408 ·Status: COMPLETED